| |
| |
| Exchange: |
|
| Security
Type: |
|
| Shares
Out: |
23,600,000 |
| Market
Cap: |
257.24(K) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.006 - $1.23 |
|
| Level
I Sector: |
|
| Level
II Sector: |
|
| Level
III Sector: |
|
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Better Therapeutics is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
2,418,738 |
8,434,200 |
| Total Buy Value |
$0 |
$0 |
$1,765,520 |
$6,943,814 |
| Total People Bought |
0 |
0 |
6 |
8 |
| Total Buy Transactions |
0 |
0 |
7 |
20 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Berman Mark A. |
Chief Medical Officer |
• – – |
2023-04-05 |
4 |
A |
$0.00 |
$0 |
D/D |
101,450 |
333,389 |
|
- |
|
| Heinen Mark |
Chief Financial Officer |
• – – |
2023-04-05 |
4 |
A |
$0.00 |
$0 |
D/D |
54,000 |
139,723 |
|
- |
|
| Wynholds Kristin |
Chief Product Officer |
• – – |
2023-04-05 |
4 |
A |
$0.00 |
$0 |
D/D |
101,450 |
200,269 |
|
- |
|
| Heinen Mark |
See Remarks |
• – – |
2022-11-30 |
4 |
A |
$1.24 |
$19,512 |
D/D |
15,723 |
85,723 |
|
- |
|
| Wynholds Kristin |
Chief Product Officer |
• – – |
2022-11-30 |
4 |
A |
$1.24 |
$4,692 |
D/D |
3,781 |
98,819 |
|
- |
|
| David P. Perry 2015 Trust |
See Remarks |
– – • |
2022-09-16 |
4 |
B |
$2.07 |
$80,975 |
D/D |
39,156 |
101,536 |
2.45 |
-38% |
|
| David P. Perry 2015 Trust |
See Remarks |
– – • |
2022-09-15 |
4 |
B |
$1.99 |
$21,623 |
D/D |
10,844 |
62,380 |
2.37 |
-34% |
|
| Karbe Frank |
See Remarks |
• • – |
2022-09-15 |
4 |
B |
$2.09 |
$104,695 |
D/D |
50,000 |
50,000 |
2.81 |
-34% |
|
| Heinen Mark |
See Remarks |
• – – |
2022-09-13 |
4 |
B |
$1.94 |
$50,696 |
D/D |
26,132 |
70,000 |
2.74 |
-21% |
|
| Heinen Mark |
See Remarks |
• – – |
2022-09-12 |
4 |
B |
$1.94 |
$46,304 |
D/D |
23,868 |
43,868 |
2.74 |
-28% |
|
| Heinen Mark |
See Remarks |
• – – |
2022-06-24 |
4 |
B |
$1.75 |
$4,000 |
I/I |
2,281 |
2,281 |
1.91 |
-24% |
|
| Armanino Andrew J. |
Director |
– • – |
2022-06-14 |
4 |
B |
$1.39 |
$20,846 |
I/I |
15,000 |
15,000 |
2.1 |
9% |
|
| Heinen Mark |
See Remarks |
• – – |
2022-06-10 |
4 |
B |
$1.56 |
$7,800 |
D/D |
5,000 |
20,000 |
2.74 |
-3% |
|
| Armanino Andrew J. |
Director |
– • – |
2022-06-09 |
4 |
B |
$1.65 |
$41,355 |
I/I |
25,000 |
151,328 |
2.1 |
-10% |
|
| Wynholds Kristin |
Chief Product Officer |
• – – |
2022-05-31 |
4 |
A |
$1.54 |
$7,728 |
D/D |
5,023 |
95,038 |
|
- |
|
| Zamirowski Justin |
Chief Commercial Officer |
• – – |
2022-05-27 |
4 |
OE |
$0.50 |
$839 |
D/D |
1,677 |
36,913 |
|
- |
|
| Zamirowski Justin |
Chief Commercial Officer |
• – – |
2022-05-16 |
4 |
OE |
$0.50 |
$17,618 |
D/D |
35,236 |
35,236 |
|
- |
|
| Heinen Mark |
See Remarks |
• – – |
2022-03-31 |
4 |
B |
$1.98 |
$9,900 |
D/D |
5,000 |
15,000 |
2.74 |
-10% |
|
| Kevin Appelbaum, Or His Successor(s), As Trustee O |
Chief Executive Officer |
– – • |
2022-03-31 |
4 |
B |
$1.97 |
$4,921 |
D/D |
2,500 |
6,250 |
2.37 |
-10% |
|
| Armanino Andrew J. |
Director |
– • – |
2022-03-29 |
4 |
B |
$2.14 |
$85,620 |
I/I |
40,000 |
126,328 |
2.1 |
-4% |
|
| Parker Geoffrey M. |
Director |
– • – |
2022-03-29 |
4 |
B |
$2.15 |
$32,231 |
D/D |
15,000 |
15,000 |
2.39 |
-4% |
|
| Lavizzo-Mourey Risa J |
Director |
– • – |
2021-12-21 |
4 |
B |
$4.60 |
$46,000 |
D/D |
10,000 |
10,000 |
2.39 |
-57% |
|
| Kevin Appelbaum, Or His Successor(s), As Trustee O |
Chief Executive Officer |
– – • |
2021-12-20 |
4 |
B |
$4.60 |
$4,600 |
D/D |
1,000 |
3,750 |
2.37 |
-57% |
|
| Kevin Appelbaum, Or His Successor(s), As Trustee O |
Chief Executive Officer |
– – • |
2021-12-15 |
4 |
B |
$4.71 |
$3,530 |
D/D |
750 |
2,750 |
2.37 |
-80% |
|
| Heinen Mark |
See Remarks |
• – – |
2021-12-15 |
4 |
B |
$4.70 |
$10,953 |
D/D |
2,333 |
10,000 |
2.74 |
-80% |
|
73 Records found
|
|
Page 2 of 3 |
|
|
